AN IMPLANTABLE EXTERNAL VASCULAR DEVICE, DESIGNED TO BE PLACED AROUND VASCULAR JOINT AND PROMOTE HEALTHY, CONTROLLED HEALING FOLLOWING ARTERIAL OR VENOUS BYPASS SURGERY
FloGuardian addresses the principal cause of vascular graft failure following vascular access, arterial and venous bypass surgery.
There are around 2 million procedures carried out each year requiring such grafts
The healthcare costs associated with haemodialysis graft failure, in the USA alone, are estimated to be in excess of $1 billion.
FloGuardian™ will be the only device on the market that addresses inhibition of both early inhibition of SMCMIH & medium to long term SMCNIH.
Excellent results achieved in pre-clinical studies, with inhibition rates at 30% – 50% inhibition of SMCNIH.